Intellectual Property

Instead of focusing on zoning and deregulation, a true abundance agenda would weaken patent and copyright monopolies that raise costs, concentrate wealth, and limit access to medicine, technology, and housing.

Healthcare costs could fall dramatically by funding research upfront and eliminating patent monopolies that drive up the price of drugs and medical equipment.

While hospital monopolies raise prices, patent protections on drugs and medical equipment are a deeper driver of high health care costs and inefficiency.

The opioid crisis shows how drug patent incentives can drive harmful behavior without meaningful reform.

Drug prices are driven by patent monopolies, making reform not just PBM regulation key to affordability.

Lower drug prices come from reforming patents and funding research, not tariffs or political dealmaking.

The rapid price decline of Ozempic in global generic markets shows that patent protections not manufacturing costs are the main reason prescription drugs remain expensive in the United States.

Publicly funded drug research—like the system proposed in Rep. Rashida Tlaib’s bill—could replace patent monopolies, reducing prices and corruption while still supporting innovation.

Genuine economic abundance requires weakening monopoly protections and financial rents that enrich the wealthy while driving up costs for everyone else.

The decline in US patent applications in 2025 signals early long-term damage to innovation from Trump’s cuts to research funding, immigration crackdowns, and broader economic policies.